Takeda Lung Cancer Therapy Innovation Pharmaceutini Pogkinib was launched and opened up a new pattern of treatment

*This document is used for the media reference, and the specific expression is confirmed by the media platform

Takeda China today announced that the innovative drugs in the field of lung cancer were officially launched. Bugininib is a new selective ALK tyrosine kinase inhibitor. It was approved by the China National Drug Administration (NMPA) in March 2022. The treatment of local advanced or metastatic non -small cell lung cancer (NSCLC), its listing will further meet the unpleasant needs of Chinese ALK -positive NSCLC patients in the current urgent need to develop a new pattern of treatment in related fields. During the listing meeting, Takeda China announced on the same day that it will support the two major authoritative institutions of the China Medical Education Association and the China Clinical Oncology Society (CSCO) non -small cell lung cancer special committee to start the "accurate target target diagnosis and treatment project of lung cancer" to jointly promote China's lung cancer Improvement of precision diagnosis and treatment.

Lung cancer is China's largest cancer, and the incidence and mortality ranks first in all malignant tumors [1]. Among them, ALK -positive NSCLC (ALK+NSCLC) is a relatively rare and dangerous subtype. The number of new cases in my country is close to 35,000 cases each year [2]. At present, such patients still have urgent clinical needs to be met in urgent clinical needs: the incidence of mental metastases in patients is high, and the quality of life has severely decreased. Data show that about 55%of patients with advanced ALK+NSCLC will have a phenomenon of brain metastases [3-5], which seriously affects the daily life of patients, and even threatens life.

Including ALK -positive mutations, more and more rare targets and the discovery of the corresponding targeted therapeutic drugs have obtained more treatment options for advanced NSCLC patients in recent years. Requirements. In order to further promote the development of accurate diagnosis and treatment of lung cancer, the "rare target target target target precision diagnosis and treatment project" was launched today. The project aims to set up a rare target target diagnosis and treatment center of cooperative hospitals across the country, and establish the hospital with the hospital as the core of lung cancer. Rare target diagnosis and treatment alliances, thereby precipitation and promotion of rare target diagnosis and treatment experience in lung cancer, and jointly promote the improvement of China's lung cancer diagnosis and treatment level.

Professor Zhou Cun, a lung hospital affiliated to Tongji University, said: "The clinical needs of patients with lung cancer with rare gene mutations are also not neglected. A good cutting -edge standardized diagnosis and treatment weapon is expected to allow more patients with lung cancer with rare mutations to obtain corresponding standardized treatment, and then comprehensively improve the diagnosis and efficacy of lung cancer in China. "

As a new ALK tyrosine kinase inhibitor, the unique bigria phosphorus (DMPO) of Butgininib can ensure high selectivity to ALK and increase the drug activity by 7 times. The characteristics of high osmosis, balanced water-soluble and lipid solutes create favorable conditions for the concentration of brain drugs through blood brain barriers; at the same time, it has a prominent inhibitory effect on common variants of EML4-ALK [6-8]. ALTA-1L research on the third phase of clinical clinical clinical of Boginib also confirms its curative effects on extending patients' survival, controlling brain metastases, and improving quality of life.

Professor Han Baohui of Shanghai Chest Hospital said: "The global III phase of clinical trial Alta-1L studies have confirmed that Pogkinib can enable patients to have no progressive survival (PFS) for the median evaluation of the independent review committee (PFS) for 2 years, and the researcher evaluation The median PFS is more than 30 months, which fully proves its overall efficacy, and is therefore recommended by the NCCN guide as the first -line recommendation of ALK -positive NSCLC treatment [9]. Looking forward to the listing of Pogginib Bring more practical clinical benefits. "

For intracranial efficacy, the ALTA-1L results show that they have a breakthrough effect on patients with baseline brain metastasis: 78%of the intracranial lesion relief rate (IOR), and the mid-level relief duration (DOR) reaches 27.9 months, surpassing the control comparison The group is more than 3 times (the control group is 26%and 9.2 months, respectively); the BIRC evaluation mid -bit PFS reaches 24 months, and the control group is 5.6 months (HR = 0.25, P <0.0001) 75%of patients with brain metastases progress or risk of death; the 3 -year OS rate for patients with first -line treatment of baseline brain metastases is 74%, and the 4 -year OS rate is as high as 71%[10].

Reference materials:

[1] Zhang Xuchao, Liu Xiaoqing, Wang Jie, et al., Chinese transgender lymphoma is positive, ROS1 positive non -small cell lung cancer diagnosis and treatment guide [J]. Chinese pathology magazine, 2018,47 (4): 7.

[2] Zhang Xunchao, Lu Shun, Tension, etc.. Chinese transgender lymphoma kinase (ALK) positive non-small cell lung cancer diagnosis and treatment guidelines [J]. Chinese pathology magazine, 2015,44 (10): 696-703.

[3] Johung kl, et al.j clin oncol 2016; 34: 123–129.

[4] Descourt R, et al.lung Cancer 2019; 136: 109–114.Huber RM, et al.6: 101–114. [5] liu c, et alont oncol.2019.

[6] Ando K, et al.Cancers (basel), 2020.

[7] Banks Wa, et al.bmc neurol.2009.

[8] Bedi S, et al.Saudi Pharm J.2018.

[9] ETtinger D, et al.j natl comprcanc netw.2022.

[10] CAMIDGE DR, et al.j clin oncol.2021.

statement:

1. This article aims to convey the frontier information of medicine, which does not constitute a recommendation or promotion of any drug or diagnosis plan.

2. If you want to know more about disease knowledge or medicine, diagnosis and treatment related information, please consult medical professionals

*This article is only used to provide scientific information to medical people, and does not represent the viewpoint of this platform

- END -